- Home
- VIVS vs PMAX Comparison
VIVS vs PMAX Comparison
Compare VIVS & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIVS | PMAX |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | Hong Kong |
| Employees | 9 | 53 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VIVS | PMAX |
|---|---|---|
| Price | $0.34 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.8M | 194.6K |
| Earning Date | 06-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.38 | N/A |
| Revenue Next Year | $15.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.20 |
| 52 Week High | $5.30 | $5.20 |
Technical Indicators
Market Signals| Indicator | VIVS | PMAX |
|---|---|---|
| Relative Strength Index (RSI) | 19.62 | 45.68 |
| Support Level | N/A | $1.61 |
| Resistance Level | $1.62 | $2.69 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 2.35 | 40.00 |
Price Performance
Historical ComparisonAbout VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About PMAX Powell Max Limited
Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.